ES2184866T3 - Composicion de tampon para reactivos de dosificado inmunologico. - Google Patents

Composicion de tampon para reactivos de dosificado inmunologico.

Info

Publication number
ES2184866T3
ES2184866T3 ES96916655T ES96916655T ES2184866T3 ES 2184866 T3 ES2184866 T3 ES 2184866T3 ES 96916655 T ES96916655 T ES 96916655T ES 96916655 T ES96916655 T ES 96916655T ES 2184866 T3 ES2184866 T3 ES 2184866T3
Authority
ES
Spain
Prior art keywords
composition
reagents
biological
tampon
immunological
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96916655T
Other languages
English (en)
Inventor
Steve D Figard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Application granted granted Critical
Publication of ES2184866T3 publication Critical patent/ES2184866T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/82—Hepatitis associated antigens and antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/826—Additives, e.g. buffers, diluents, preservatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Detergent Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

UNA COMPOSICION ACUOSA APROPIADA PARA SU USO DURANTE LA REALIZACION DE PROCEDIMIENTOS INMUNOLOGICOS. LA COMPOSICION INCLUYE AL MENOS UN TAMPON BIOLOGICO, DITIOTREITOL (ALTERNATIVAMENTE REFERIDO AQUI COMO "DTT ), Y ETILENGLICOL. LA COMPOSICION PUEDE INCLUIR TAMBIEN AL MENOS UN DETERGENTE BIOLOGICO, AL MENOS UNA FUENTE DE CONTRAIONES POSITIVOS Y NEGATIVOS, P. EJ. SAL, Y AL MENOS UN MODIFICADOR DE VISCOSIDAD, P. EJ. AZUCAR. EL TAMPON TAMBIEN PUEDE INCLUIR AL MENOS UN CONSERVANTE, COMO AZIDA SODICA. EL PH DE LA COMPOSICION VARIA PREFERENTEMENTE DESDE ALREDEDOR DE 6,4 A 7,2. TAMBIEN SE REVELA UN KIT QUE CONTIENE LA COMPOSICION.
ES96916655T 1995-06-07 1996-05-24 Composicion de tampon para reactivos de dosificado inmunologico. Expired - Lifetime ES2184866T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/482,710 US5616460A (en) 1995-06-07 1995-06-07 Buffer composition for reagents for immunoassay

Publications (1)

Publication Number Publication Date
ES2184866T3 true ES2184866T3 (es) 2003-04-16

Family

ID=23917128

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96916655T Expired - Lifetime ES2184866T3 (es) 1995-06-07 1996-05-24 Composicion de tampon para reactivos de dosificado inmunologico.

Country Status (7)

Country Link
US (2) US5616460A (es)
EP (1) EP0852009B1 (es)
JP (2) JP4101874B2 (es)
AT (1) ATE223046T1 (es)
DE (1) DE69623303T2 (es)
ES (1) ES2184866T3 (es)
WO (1) WO1996041164A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
CA2635352C (en) * 1997-06-13 2012-09-11 Genentech, Inc. Stabilized antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
AU9498098A (en) * 1997-09-22 1999-04-12 Chiron Corporation Buffers for stabilizing antigens
DE69837155T2 (de) 1997-09-22 2007-06-21 Novartis Vaccines and Diagnostics, Inc., Emeryville Verfahren zum nachweiss von antikörpern in einer probe
DK1071955T4 (da) * 1998-04-17 2009-06-15 Innogenetics Nv Forbedrede immundiagnostiske assays, som anvender reduktionsmidler
US6623921B2 (en) 1998-07-30 2003-09-23 Advanced Life Science Institute, Inc. Method for measurement of hepatitis C virus
CA2305192C (en) 1998-07-30 2009-10-13 Advanced Life Science Institute, Inc. Method for assaying hepatitis c virus
DE10013794A1 (de) * 2000-03-15 2001-10-11 Gluesenkamp Karl Heinz Herstellung, Stabilisierung und Anwendung einer neuen Art von chemisch aktivierten Oberflächen
WO2002008761A1 (en) * 2000-07-21 2002-01-31 Cuno Incorporated Improved blocking chemistries for nylon membrane
EP1311860A2 (en) * 2000-08-21 2003-05-21 Queen's University At Kingston Methods and kits for separation and detection of proteins in biological samples
US20030170618A1 (en) * 2001-02-02 2003-09-11 Chien David Y. Buffers for stabilizing antigens
SG118120A1 (en) * 2001-03-28 2006-01-27 Ortho Clinical Diagnostics Inc A hepatitis C antigen - antibody combination assayfor the early detection of HCV infection
JP2003066047A (ja) * 2001-06-14 2003-03-05 Matsushita Electric Ind Co Ltd 免疫反応測定方法及びそれに用いる免疫反応測定用試薬
US7101683B2 (en) 2001-06-26 2006-09-05 Abbott Laboratories Methods for the simultaneous detection of HCV antigens and HCV antibodies
CH698246B1 (de) * 2001-12-20 2009-06-30 Hoffmann La Roche Test zur Identifizierung von Inhibitoren von Beta-Sekretasen.
US20030157556A1 (en) * 2002-02-13 2003-08-21 Maggiore Jack A. Biological fluid stabilizing composition and method of use thereof
WO2003102246A1 (en) * 2002-05-31 2003-12-11 Penn State Research Foundation Dot-elisa for the detection of animal viruses
US20040152070A1 (en) * 2003-02-04 2004-08-05 Shah Dinesh O. Method of detection of HCV antibodies in combination assay or sole antibody assay
US20050014136A1 (en) * 2003-05-28 2005-01-20 Innogenetics N.V. Modified HCV NS5
CA2544185C (en) * 2003-10-28 2010-09-28 Advanced Life Science Institute, Inc. Method of detecting hepatitis c virus
ATE476658T1 (de) * 2004-02-26 2010-08-15 Candor Bioscience Gmbh Wässrige lösung zur verwendung als medium für die spezifischen bindungsreaktion eines bindespaares
CN104090097B (zh) * 2004-02-26 2017-04-12 康多尔生物技术有限公司 一种用作结合对的特异性结合反应培养基的水溶液
US7867443B2 (en) * 2004-07-23 2011-01-11 Dako Denmark A/S Method and apparatus for automated pre-treatment and processing of biological samples
US20080108147A1 (en) * 2006-11-03 2008-05-08 Tie Wei Reduction of non-specific binding in immunoassays
JP2007084579A (ja) * 2006-12-28 2007-04-05 Mitsubishi Pharma Corp ヘパリン溶液入りプレフィルドシリンジ製剤およびその製造方法
US8617820B2 (en) * 2007-08-28 2013-12-31 Ortho-Clinical Diagnostics, Inc. Use of glycosaminoglycans to reduce non-specific binding in immunoassays
JP5416159B2 (ja) * 2011-03-31 2014-02-12 富士フイルム株式会社 高感度なイムノクロマトグラフ方法
CN103630690B (zh) * 2013-12-17 2014-08-20 朱之炜 丙型肝炎病毒抗原抗体联合检测试剂盒及其检测方法
EP3258270B1 (en) * 2015-02-10 2019-05-29 Shenzhen New Industries Biomedical Engineering Co. Ltd. Cardiac troponin i ultra-sensitive detection reagent kit, and ultra-sensitive detection method therefor
US12493034B2 (en) * 2021-01-08 2025-12-09 George Mason University Reagent buffer
CN114200125B (zh) * 2021-12-06 2024-02-13 武汉生之源生物科技股份有限公司 一种不含蛋白的碱性磷酸酶-抗体偶联物稀释液及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59198999A (ja) * 1983-04-27 1984-11-10 Denka Seiken Co Ltd クレアチンキナ−ゼ測定用組成物
JPS6339582A (ja) * 1986-08-04 1988-02-20 Takara Shuzo Co Ltd 酵素組成物
US4956274A (en) * 1987-04-06 1990-09-11 Microgenics Corporation Reagent stabilization in enzyme-donor and acceptor assay
US5075221A (en) * 1988-10-07 1991-12-24 Eastman Kodak Company Stabilized extraction composition containing a sulfhydryl-containing reducing agent and its use in chlamydial and gonococcal determinations
WO1990006127A1 (fr) * 1988-12-06 1990-06-14 Otsuka Pharmaceutical Co., Ltd. COMPOSITION D'INTERLEUKINE-1β STABILISEE
DE69132332T2 (de) * 1990-04-06 2000-11-30 Genelabs Technologies, Inc. Hepatitis c-virus-epitope
AU2679492A (en) * 1991-09-16 1993-04-27 Abbott Laboratories Hepatitis c assay
US5376313A (en) * 1992-03-27 1994-12-27 Abbott Laboratories Injection molding a plastic assay cuvette having low birefringence
GR1001480B (el) * 1992-12-29 1994-02-28 Eyaggelia Protopapa Ενζυμικά σκευάσματα περιέχοντα παπαϊνη ή χυμο?ρυψίνη και μέ?οδοι μόνιμης ενζυμικής αποτρίχωσης.

Also Published As

Publication number Publication date
US5616460A (en) 1997-04-01
ATE223046T1 (de) 2002-09-15
DE69623303D1 (de) 2002-10-02
JP3930519B2 (ja) 2007-06-13
WO1996041164A1 (en) 1996-12-19
DE69623303T2 (de) 2003-04-17
EP0852009A1 (en) 1998-07-08
JP4101874B2 (ja) 2008-06-18
JP2001516440A (ja) 2001-09-25
JP2005300552A (ja) 2005-10-27
EP0852009B1 (en) 2002-08-28
US5773212A (en) 1998-06-30

Similar Documents

Publication Publication Date Title
ES2184866T3 (es) Composicion de tampon para reactivos de dosificado inmunologico.
AU594488B2 (en) Agents for the treatment of arthroses
EP0695171A1 (en) GONADOTROPINE CONTAINING FREEZER DRIED DROPS
TR199701212T1 (xx) �drar� tutamama halinin tedavisi i�in alfa IL- agonistlerinin kullan�lmas�.
ES2159552T3 (es) Terapia de sustitucion de hormonas.
MX9707535A (es) Uso de derivados de vitamina d2 o de vitamina d4 en la preparacion de un farmaco para el tratamiento de hiperparatiroidismo secundario.
MY107158A (en) 3-arylcarbonyl; -1h-indoles useful as therapeutic agents.
ES2053442T3 (es) Un preparado de trombina.
ZA9810444B (en) Use of 9-deoxy-2',9-methano-3-oxa-4,5,6-trinor-3,7-(1',3'interphenylene)-13,14-dihydroprostaglandin F1 to treat peripheral vascular disease
NZ332625A (en) Concentrated antibody preparation containing greater than 100 mg/ml of the antibody
ES2037742T3 (es) Procedimiento de obtencion de una composicion para administracion intravenosa.
ES8300104A1 (es) Un procedimiento para obtener derivados de benzopirano
CA2008304A1 (en) Assay for bone alkaline phosphatase
FR2651435B1 (es)
ES2045768T3 (es) Composiciones topicas que contienen defibrotida.
PT952975E (pt) Compostos bi-aromaticos ligados por um radical hetero-etinileno e composicoes farmaceuticas e cosmeticas que os contem
ES2136724T3 (es) Emulsion liofilizada, que contiene una sustancia activa.
FI852730L (fi) (pyrrol-1-yl) -fenyl-dihydropyridazinoner, deras framstaellning och anvaendning.
SE8100623L (sv) Topiskt, indomentacinhaltigt lekemedel
PT89742A (pt) Processo de preparacao de 24r-cimnol e de suas composicoes farmaceuticas
IT8719974A0 (it) Dispositivo per l'adduzione dosata di lega leggera liquida nel cilindro di pressione.
ES2093135T3 (es) Anticuerpos monoclonales contra el complejo plasmina-antiplasmina, procedimiento para su preparacion asi como su utilizacion.
AU560165B2 (en) Chromophoric peptides
AR014969A1 (es) Formulacion que contienen por lo menos una proteina tardia (proteina l) de uno o mas papilomavirus y/o por lo menos una proteina temprana (proteina e) deuno o mas papilomavirus, procedimiento para la preparacion de la formulacion mencionada asi como su utilizacion para la manufactura de un medicamen
DE69614552D1 (de) MODIFIZIERTE ALPHA-D-GLCP-(1,2)-ALPHA-D-Glcp-(1,3)-ALPHA-D-Glcp-ANALOGE